The mean platelet volume and atherosclerotic cardiovascular-risk factors in adults with obesity: a systematic review and meta-analysis of observational studies.
Journal
BMC nutrition
ISSN: 2055-0928
Titre abrégé: BMC Nutr
Pays: England
ID NLM: 101672434
Informations de publication
Date de publication:
16 May 2022
16 May 2022
Historique:
received:
16
05
2021
accepted:
26
04
2022
entrez:
16
5
2022
pubmed:
17
5
2022
medline:
17
5
2022
Statut:
epublish
Résumé
Obesity is a major risk factor for atherosclerotic cardiovascular disease (ASCVD) and is associated with altered platelet function. The mean platelet volume (MPV) is a rapid measure of platelet activation and a prognostic marker in patients with cardiovascular disease. However, no meta-analysis on the association between MPV and obesity has been conducted, and the value of monitoring the MPV in patients with obesity remains unclear. To provide cumulative evidence on whether the mean platelet volume (MPV) is increased in individuals with obesity and to describe associations between the ASCVD-risk factors and the MPV in individuals with obesity. This meta-analysis was prepared following the Meta-analysis Of Observational Studies (MOOSE) guidelines. We searched the PubMed and Embase database from inception until the 31st of March 2021. Studies were included when they reported the mean platelet volume in individuals with obesity and provided a suitable non-obese comparator group. The risk of bias was independently assessed by two reviewers using the Newcastle-Ottawa scale. The primary outcome of the meta-analysis was the MPV, while we considered the atherosclerotic risk profiles as a secondary outcome. We identified 178 citations through the PUBMED and 255 citations through EMBASE database search. In all, 13 studies met the inclusion criteria. Firstly, we report an increased mean platelet volume in individuals with obesity compared to non-obese individuals (MD 0.79; [95%CI: 0.42 to 1.16], I2 = 93.4%). Moreover, the reported increase in the MPV was inversely associated with the body mass index (Coefficient: -0.57, standard error (SE): 0.18, p < 0.001) and directly related to changes in triglyceride levels (Coefficient: 4.99, standard error (SE): 1.14, p < 0.001). This meta-analysis and meta-regression showed an increased MPV in nondiabetic individuals living with obesity. Moreover, the MPV was associated with hypertriglyceridemia, an independent predictor of atherosclerotic cardiovascular disease. Overall, the findings suggest that MPV may be a valuable rapid marker for the monitoring and risk-stratification of individuals with obesity who may be at risk of developing cardiovascular disease.
Sections du résumé
BACKGROUND
BACKGROUND
Obesity is a major risk factor for atherosclerotic cardiovascular disease (ASCVD) and is associated with altered platelet function. The mean platelet volume (MPV) is a rapid measure of platelet activation and a prognostic marker in patients with cardiovascular disease. However, no meta-analysis on the association between MPV and obesity has been conducted, and the value of monitoring the MPV in patients with obesity remains unclear.
OBJECTIVE
OBJECTIVE
To provide cumulative evidence on whether the mean platelet volume (MPV) is increased in individuals with obesity and to describe associations between the ASCVD-risk factors and the MPV in individuals with obesity.
METHODS
METHODS
This meta-analysis was prepared following the Meta-analysis Of Observational Studies (MOOSE) guidelines. We searched the PubMed and Embase database from inception until the 31st of March 2021. Studies were included when they reported the mean platelet volume in individuals with obesity and provided a suitable non-obese comparator group. The risk of bias was independently assessed by two reviewers using the Newcastle-Ottawa scale. The primary outcome of the meta-analysis was the MPV, while we considered the atherosclerotic risk profiles as a secondary outcome.
RESULTS
RESULTS
We identified 178 citations through the PUBMED and 255 citations through EMBASE database search. In all, 13 studies met the inclusion criteria. Firstly, we report an increased mean platelet volume in individuals with obesity compared to non-obese individuals (MD 0.79; [95%CI: 0.42 to 1.16], I2 = 93.4%). Moreover, the reported increase in the MPV was inversely associated with the body mass index (Coefficient: -0.57, standard error (SE): 0.18, p < 0.001) and directly related to changes in triglyceride levels (Coefficient: 4.99, standard error (SE): 1.14, p < 0.001).
CONCLUSION
CONCLUSIONS
This meta-analysis and meta-regression showed an increased MPV in nondiabetic individuals living with obesity. Moreover, the MPV was associated with hypertriglyceridemia, an independent predictor of atherosclerotic cardiovascular disease. Overall, the findings suggest that MPV may be a valuable rapid marker for the monitoring and risk-stratification of individuals with obesity who may be at risk of developing cardiovascular disease.
Identifiants
pubmed: 35578358
doi: 10.1186/s40795-022-00541-8
pii: 10.1186/s40795-022-00541-8
pmc: PMC9109381
doi:
Types de publication
Journal Article
Langues
eng
Pagination
47Subventions
Organisme : National research foundation, South Africa
ID : 107519
Informations de copyright
© 2022. The Author(s).
Références
Lancet. 2004 Jan 10;363(9403):157-63
pubmed: 14726171
J Clin Epidemiol. 2011 Apr;64(4):401-6
pubmed: 21208779
Rev Assoc Med Bras (1992). 2019 Oct 10;65(9):1182-1187
pubmed: 31618335
Br J Haematol. 2003 Jan;120(1):169-70
pubmed: 12492596
Int J Clin Pract. 2005 Aug;59(8):981-2
pubmed: 16033624
Diabetes. 2017 Apr;66(4):1074-1085
pubmed: 28052964
PLoS One. 2015 Jun 09;10(6):e0129677
pubmed: 26058081
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Future Cardiol. 2008 Jan;4(1):33-55
pubmed: 19804271
J Cardiol. 2010 Sep;56(2):154-8
pubmed: 20430587
Pediatr Obes. 2012 Aug;7(4):284-94
pubmed: 22715120
Clin Nephrol. 2015 Jun;83(6):322-9
pubmed: 25943143
Am J Clin Nutr. 1997 May;65(5 Suppl):1665S-1668S
pubmed: 9129507
Blood. 2013 Nov 14;122(20):3415-22
pubmed: 24092932
Circulation. 2008 Jan 1;117(1):93-102
pubmed: 18086925
NCHS Data Brief. 2020 Feb;(360):1-8
pubmed: 32487284
J Pediatr Endocrinol Metab. 2010 Aug;23(8):807-13
pubmed: 21073123
Asia Pac J Clin Nutr. 2018;27(1):182-188
pubmed: 29222897
Circulation. 2021 May 25;143(21):e984-e1010
pubmed: 33882682
Eur Rev Med Pharmacol Sci. 2016 Apr;20(7):1300-6
pubmed: 27097950
Clin Appl Thromb Hemost. 2003 Jul;9(3):177-90
pubmed: 14507105
Thromb Res. 2007;120(2):245-50
pubmed: 17145074
Res Synth Methods. 2021 Jan;12(1):55-61
pubmed: 32336025
Platelets. 2007 May;18(3):212-6
pubmed: 17497433
Acta Haematol. 2019;142(3):149-153
pubmed: 31189163
JAMA Netw Open. 2018 Nov 2;1(7):e183788
pubmed: 30646365
J Cardiovasc Pharmacol. 2004 Apr;43(4):514-21
pubmed: 15085062
Circulation. 2019 Jun 18;139(25):e1162-e1177
pubmed: 30586766
Folia Med Cracov. 2014;54(2):55-64
pubmed: 25648310
J Endocrinol Invest. 2016 Jan;39(1):45-53
pubmed: 26100531
Platelets. 2012;23(1):45-50
pubmed: 21736420
Natl Health Stat Report. 2018 Dec;(122):1-16
pubmed: 30707668
Int J Clin Exp Med. 2015 Dec 15;8(12):22557-63
pubmed: 26885242
Blood Coagul Fibrinolysis. 2012 Jul;23(5):388-90
pubmed: 22473052
J Thromb Haemost. 2010 Jan;8(1):148-56
pubmed: 19691485
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459